Your CDx Partner from Translational Research to Global Commercialization

Accelerate access to treatment

Our vision is to democratize NGS globally and bring genomic testing closer to patients.

Our highly automated and end-to-end solutions enable a broad spectrum of laboratories to provide genomic profiling with rapid turnaround time, bringing precision oncology to more patients everywhere.

Why is Oncomine Solutions the preferred choice for pharma?

Learn more about our CDx partnerships

Our Technology     Our Solutions

Latest Companion Diagnostic News​    Global Approvals & Commercialization​

Oncomine Dx Target Test CDx Indications

Global Approvals and Commercialization

Oncomine Dx Target Test, is approved and reimbursed by government and commercial insurers in over 15 countries, covering more than 550 million lives globally.

Not all therapies are approved in all regions. Please refer to the intended use per country for details.

Have questions? Request a CDx consultation.

*For In Vitro Diagnostic Use.

** For In Vitro Diagnostic Use. Not available in all countries including the United States.

Abbreviated Intended Use: The Oncomine Dx Target Test is a qualitative in vitro diagnostic test that uses targeted high-throughput, parallel sequencing technology to detect single-nucleotide variants (SNVs), insertions, and deletions in 23 genes from DNA and fusions in ROS1 and RET from RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from patients with non–small cell lung cancer (NSCLC), IDH1 R132 mutations from FFPE tumor tissue samples from patients with cholangiocarcinoma (CC) and RET SNVs, MNVs, and deletions from DNA isolated from FFPE tumor tissue samples from patients with medullary thyroid cancer (MTC), and RET fusions from RNA isolated from FFPE tumor tissue samples from patients with thyroid cancer (TC) using the Ion PGM Dx System.

Abbreviated Intended Use: The Oncomine Dx Express Test is a qualitative in vitro diagnostic test that uses targeted next-generation sequencing (NGS) technology and the Ion Torrent Genexus Dx System to detect deletions, insertions, substitutions, and copy number gain present in 42 genes and fusions in 18 genes from DNA and RNA extracted from formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples. The Oncomine Dx Express Test also detects deletions, insertions and substitutions in 42 genes and fusions in 7 genes from cfTNA extracted from plasma samples. The Oncomine Dx Express Test is intended to provide clinically relevant tumor mutation profiling information to be used by qualified health care professionals in accordance with professional guidelines as an aid in therapy management of cancer patients with solid malignant neoplasms using FFPE samples and as an aid in therapy management of cancer patients with non-small cell lung cancer using plasma samples. It is not conclusive or prescriptive for labeled use of any specific therapeutic product.